The FDA has given priority status to experimental vaccines from Pfizer and BioNTech

According to the results of the first tests, the vaccine showed effectiveness against coronavirus.

The US food and drug administration (FDA) on Monday gave priority status to two experimental coronavirus vaccines jointly developed by German biotech company BioNTech and US pharmaceutical giant Pfizer.

The BNT162b1 and BNT162b2 vaccines are at the most advanced stage among at least four currently undergoing clinical trials in the United States and Germany.

Before the start of trading, Pfizer shares rose by 2%, and BioNTech shares listed in the United States – by 6%.

Earlier this month, the companies said that the BNT162b1 vaccine showed potential effectiveness against the virus and gave reasonable tolerance rates after the first human trials.

Preliminary results of BNT162b1 research in Germany are expected in July, the companies say.

If the trials are successful and the vaccines receive regulatory approval, the companies plan to produce up to 100 million doses by the end of this year and more than 1.2 billion treatments by the end of 2021.

If permission is granted, the companies plan to launch large-scale trials involving 30,000 people this month.
The FDA assigns priority status to the most promising vaccines and medications.